{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:53:39Z","timestamp":1785887619809,"version":"3.56.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:31:03Z","timestamp":1775129463000},"page":"176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re: Bacillus Calmette-Gu\u00e9rin Plus Mitomycin Versus Bacillus Calmette-Gu\u00e9rin Alone for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve Non\u2013muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)"],"prefix":"10.1016","volume":"90","author":[{"given":"Daoyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.011_b0005","doi-asserted-by":"crossref","unstructured":"Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Gu\u00e9rin plus mitomycin versus Bacillus Calmette-Gu\u00e9rin alone for Bacillus Calmette-Gu\u00e9rin-na\u00efve non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP 1301). Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2026.01.009.","DOI":"10.1016\/j.eururo.2026.01.009"},{"key":"10.1016\/j.eururo.2026.03.011_b0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2025.03.023","article-title":"Urine tumor DNA to stratify the risk of recurrence in patients treated with atezolizumab for Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"88","author":"St-Laurent","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.011_b0015","doi-asserted-by":"crossref","unstructured":"Katims AB, White C, Alam SM, et al. Urinary biomarkers objectively measure minimal residual disease in non-muscle-invasive bladder cancer. Clin Cancer Res. In press. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3395.","DOI":"10.1158\/1078-0432.CCR-25-3395"},{"key":"10.1016\/j.eururo.2026.03.011_b0020","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-21-0205","article-title":"Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of Bacillus Calmette-Gu\u00e9rin immunotherapy in non-muscle-invasive bladder cancer","volume":"27","author":"Damrauer","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.03.011_b0025","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2025.12.054","article-title":"Field-effect-informed urine liquid biopsy for bladder cancer","volume":"189","author":"Shi","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2026.03.011_b0030","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.euo.2025.04.006","volume":"8","author":"Packiam","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:07Z","timestamp":1785885967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283826020452"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Bacillus Calmette-Gu\u00e9rin Plus Mitomycin Versus Bacillus Calmette-Gu\u00e9rin Alone for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve Non\u2013muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}